MILPITAS, Calif.--(BUSINESS WIRE)--Bigfoot Biomedical, Inc., a diabetes solutions company using artificial intelligence to optimize the dosing and delivery of insulin for people with insulin-requiring diabetes, has been included as part of a demonstration showcasing new Android security features at the annual Google I/O developer conference in Mountain View, California.
Insulin requirements are dynamic and fluctuate throughout the day, and insulin can be deadly if incorrectly dosed. Bigfoot Loop, an investigational Class III automated insulin delivery system, is designed to fully and securely integrate with an off-the-shelf commercial smartphone.
The session will present as a use case how the Bigfoot system on an Android platform could leverage Android’s secure confirmations API to authenticate insulin dose communications requested from an app on the smartphone. This authentication is intended to reduce the risk of doses being requested or altered by unauthorized actors.
“We are thrilled to be a medical device use case for a Google I/O session on enhanced mobile security features,” said Bryan Mazlish, co-founder and chief product officer of Bigfoot Biomedical. “When I first began designing a solution for my own family that was centered around the use of a smartphone, it became clear to me that the risk and vulnerability inherent in connected systems would have to be managed in the earliest stages of design. That’s why I’m excited now to see Bigfoot at the forefront of developing smart, connected medical devices with sophisticated approaches to security. New mobile security features such as the Android Protected Confirmation API have the potential to give Bigfoot users even more confidence that their security is a priority for us.”
Bigfoot’s systems are designed to be secure, encrypted, and authenticated. In addition to collaborating with smartphone manufacturers in making use of advanced security features, Mazlish holds a seat on the steering committee of the Diabetes Technology Society working group to develop security standards for mobile platforms intended to safeguard users of connected medical devices.
Bigfoot Biomedical anticipates a commercial launch of two systems, Bigfoot Loop and Bigfoot Inject, in 2020, pending completion of a pivotal clinical trial and subsequent regulatory approvals for each.
About Bigfoot Biomedical, Inc.
Bigfoot Biomedical was founded by a team of people with a personal connection to type 1 diabetes. With its Loop and Inject systems, the company seeks to reduce the burden of living with insulin-requiring diabetes and to maximize the leverage of health care providers through data, connectivity, automation, and artificial intelligence. Learn more at bigfootbiomedical.com. Follow us on Twitter @BigfootBiomed and Facebook.